Literature DB >> 2303321

3-Deazaadenosine--an inhibitor of interleukin 1 production by human peripheral blood monocytes.

J A Schmidt1, R Bomford, X M Gao, J Rhodes.   

Abstract

3-Deazaadenosine (c3Ado) has been reported to have properties of an immunosuppressive and anti-inflammatory agent. This study was designed to investigate whether c3Ado might exert anti-inflammatory activities through inhibiting Interleukin 1 (IL-1). c3Ado was found to be a potent inhibitor of IL-1 production by LPS stimulated human peripheral blood monocytes and acted at the level of synthesis rather than secretion. c3Ado also had direct effects on IL-1 biological activity in two separate assays; thymocyte proliferation and induction of prostaglandin release. Further experiments indicated that c3Ado also inhibited growth factor dependent proliferation driven by both Interleukin-2 and Interleukin-3 as well as the proliferation of a number of non-growth factor dependent cells. However, short term exposure to c3Ado resulted in no inhibition of 3H-thymidine incorporation by cells but a significant inhibition of 3H-uridine uptake into TCA precipitable material. These results suggest that c3Ado is a selective inhibitor of RNA synthesis and inhibits IL-1 production and activity by blocking new messenger RNA production induced by LPS or IL-1. General inhibition of RNA synthesis would also account for its anti-proliferative activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303321     DOI: 10.1016/0192-0561(90)90071-t

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  1 in total

1.  Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains.

Authors:  D L Mayers; J A Mikovits; B Joshi; I K Hewlett; J S Estrada; A D Wolfe; G E Garcia; B P Doctor; D S Burke; R K Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.